title: A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans.
abstract: In an open study, we compared the efficacy of single doses of oral ivermectin (12 mg) and oral albendazole (400 mg) for the treatment of cutaneous larva migrans. Twenty-one patients were randomly assigned to receive ivermectin (n = 10) or albendazole (n = 11). All patients who received ivermectin responded and none relapsed (cure rate = 100%). All but one patient in the group receiving albendazole responded, but five relapsed after a mean of 11 days (cure rate = 46%; P = 0.017). No major adverse effects were observed. We conclude that a single 12-mg dose of ivermectin is more effective than a single 400-mg dose of albendazole for the treatment of cutaneous larva migrans.
authors.affiliation: Departement de Maladies Infectieuses, Parasitaires, Tropicales et Sante Publique, Hopital de la Pitie-Salpetriere, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Caumes
authors.forename: J
authors.initials: J
authors.lastname: Carriere
authors.forename: A
authors.initials: A
authors.lastname: Datry
authors.forename: P
authors.initials: P
authors.lastname: Gaxotte
authors.forename: M
authors.initials: M
authors.lastname: Danis
authors.forename: M
authors.initials: M
authors.lastname: Gentilini
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D015766:Albendazole / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007559:Ivermectin / Q000008:administration & dosage / Q000627:therapeutic use*; D007815:Larva Migrans / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014195:Travel
chemical_list: D007559:Ivermectin; D015766:Albendazole